Download Free Sample
Buy Now
Table of Contents
1.1. Context
1.2. Project Objectives
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis
6.1. Overview of Next Generation RNA Therapeutics and Vaccines
6.2. Evolution of Next Generation RNA Therapeutics and Vaccines
6.3. Types of Next Generation RNA Molecules
6.4. Key Aspects of Next Generation RNA Molecules
6.5. Key Challenges Associated with Traditional RNA Modalities
6.6. Advantages of Using Next Generation RNA Modalities
7.1. Overview of RNA Therapeutics and RNA Vaccines Therapies
7.1.1. Analysis by Type of Modality
7.1.2. Analysis by Type of Molecule
7.1.3. Analysis by Delivery Vehicle
7.1.4. Analysis by Stage of Development
7.1.5. Analysis by Therapeutic Area
7.1.6. Most Active Players: Analysis by Number of Therapies
7.2. RNA Therapeutics and RNA Vaccines: Clinical Stage Therapies Landscape
7.2.1. Analysis by Phase of Development
7.2.2. Analysis by Route of Administration
7.2.3. Analysis by Therapeutic Area
7.3. RNA Therapeutics and RNA Vaccines: Therapy Developers Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.4. RNA Therapeutics and RNA Vaccines: Self-amplifying RNA Therapies Landscape
7.4.1. Analysis by Phase of Development
7.4.2. Analysis by Therapeutic Area
7.4.3. Most Active Players: Analysis by Number of Therapies
7.5. RNA Therapeutics and RNA Vaccines: Circular RNA Therapies Landscape
7.5.1. Analysis by Phase of Development
7.5.2. Analysis by Therapeutic Area
7.5.3. Most Active Players: Analysis by Number of Therapies
8.1. Overview of RNA Therapeutics and RNA Vaccines Technologies
8.1.1. Analysis by Class of Molecule
8.1.2. Analysis by Type of Molecule
8.1.3. Analysis by Capabilities of the Technology
8.1.4. Analysis by Therapeutic Area
8.1.5. Analysis by Highest Stage of Development
8.1.6. Analysis by Class of Molecule and Therapeutic Area
8.1.7. Analysis by Class of Molecule and Highest Stage of Development
8.1.8. Analysis by Type of Molecule and Capabilities of the Technology
8.2. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technology / Platform Developers Landscape
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Operational Model
9.1. ARCT-154
9.1.1. Company Overview
9.1.2. Drug Overview
9.1.3. Clinical Trial Information
9.1.4. Clinical Trial Endpoints
9.1.5. Clinical Trial Results
9.2. Gemcovac
9.3. VLPCOV-01
9.4. AVX901
9.5. BNT161
9.6. MTL-CEBPA + Sorafenib
10.1. Methodology and Key Parameters
10.2. RNA Therapeutics and RNA Vaccines: Clinical Trial Analysis
10.2.1. Analysis by Trial Registration Year
10.2.2. Analysis by Trial Status
10.2.3. Analysis by Trial Registration Year and Trial Status
10.2.4. Analysis by Trial Phase
10.2.5. Analysis of Patients Enrolled by Trial Phase
10.2.6. Analysis of Patients Enrolled by Trial Registration Year
10.2.7. Analysis by Study Design
10.2.8. Analysis by Target Patient Population
10.2.9. Analysis by Patient Gender
10.2.10. Analysis by Type of Sponsor / Collaborator
10.2.11. Analysis by Therapeutic Area
10.2.12. Most Active Players: Analysis by Number of Trials
10.2.13. Analysis by Geography
11.1. Methodology and Key Parameters
11.2. RNA Therapeutics and RNA Vaccines: Patent Analysis
11.2.1. Analysis by Publication Year
11.2.2. Analysis by Type of Patent
11.2.3. Analysis of Granted Patents and Patent Applications by Publication Year
11.2.4. Analysis by Type of Applicant
11.2.5. Analysis by Application Year
11.2.6. Analysis by Patent Jurisdiction (Region)
11.2.7. Analysis by Patent Jurisdiction (Country)
11.2.8. Analysis by Patent Age
11.2.9. Leading Industry Players: Analysis by Number of Patents
11.2.10. Leading Non-Industry Players: Analysis by Number of Patents
11.2.11. Leading Individual Assignees: Analysis by Number of Patents
11.2.12. Analysis by CPC Symbols
11.3. Patent Benchmarking Analysis
11.4. Patent Valuation Analysis
12.1. Partnership Models
12.2. RNA Therapeutics and RNA Vaccines: Partnerships and Collaborations
12.2.1. Analysis by Year of Partnership
12.2.2. Analysis by Type of Partnership
12.2.3. Analysis by Year and Type of Partnership
12.2.4. Analysis by Year of Partnership and Type of Molecule
12.2.5. Analysis by Purpose of Partnership
12.2.6. Analysis by Focus Area of Partnership
12.2.7. Analysis by Therapeutic Area
12.2.8. Most Active Players: Analysis by Number of Partnerships
12.2.9. Analysis by Geography
12.2.9.1. Local and International Deals
12.2.9.2. Intracontinental and Intercontinental Deals
13.1. Funding Models
13.2. Funding Lifecycle Analysis
13.3. Investment Case: Risk and Return
13.4. RNA Therapeutics and RNA Vaccines: Funding and Investment Analysis
13.4.1. Analysis by Year of Funding
13.4.2. Analysis by Type of Funding
13.4.3. Analysis by Year and Type of Funding
13.4.4. Analysis of Amount Invested by Year of Funding
13.4.5. Analysis of Amount Invested by Type of Funding
13.4.6. Analysis by Geography
13.4.7. Analysis by Type of Molecule
13.4.8. Analysis by Purpose of Funding
13.4.9. Analysis by Stage of Development
13.4.10. Analysis by Therapeutic Area
13.4.11. Most Active Players: Analysis by Number of Funding Instances
13.4.12. Most Active Players: Analysis by Amount Invested
13.4.13. Most Active Investors: Analysis by Number of Funding Instances
13.5. Evolution and Relative Assessment of Funding Models
13.6. Summary of Funding and Investment Opportunities
14.1. Analysis Methodology
14.2. RNA Therapeutics and RNA Vaccines: Big Pharma Initiatives
14.2.1. Most Active Players: Analysis by Number of Big Pharma Initiatives
14.2.2. Analysis by Year of Initiative
14.2.3. Analysis by Type of Initiative
14.2.4. Analysis by Focus Area of Initiative
14.2.5. Analysis by Purpose of Initiative
14.2.6. Analysis by Type of Molecule
14.2.7. Analysis by Therapeutic Area
14.2.8. Analysis by Location of Headquarters
15.1. Forecast Model
15.2. Key Assumptions
15.3. Forecast Methodology
15.4. Global Next Generation RNA Therapeutics Market: Forecasted Estimates (till 2035)
15.4.1. Scenario Analysis
15.4.1.1. Conservative Scenario
15.4.1.2. Optimistic Scenario
15.5. Key Market Segmentations
16.1. Next Generation RNA Therapeutics Market: Distribution by Type of Modality
16.1.1. Next Generation RNA Therapeutics Market for Therapeutics: Forecasted Estimates (till 2035)
16.1.2. Next Generation RNA Therapeutics Market for Vaccines: Forecasted Estimates (till 2035)
17.1. Next Generation RNA Therapeutics Market: Distribution by Type of Molecule
17.1.1. Next Generation RNA Therapeutics Market for sacRNA: Forecasted Estimates (till 2035)
17.1.2. Next Generation RNA Therapeutics Market for saRNA: Forecasted Estimates (till 2035)
17.1.3. Next Generation RNA Therapeutics Market for circRNA: Forecasted Estimates (till 2035)
18.1. Next Generation RNA Therapeutics Market: Distribution by Target Indication
18.1.1. Next Generation RNA Therapeutics Market for Hepatocellular Carcinoma: Forecasted Estimates (till 2035)
18.1.2. Next Generation RNA Therapeutics Market for Seasonal Influenza: Forecasted Estimates (till 2035)
18.1.3. Next Generation RNA Therapeutics Market for Advanced Solid Tumors: Forecasted Estimates (till 2035)
18.1.4. Next Generation RNA Therapeutics Market for Radiation-Induced Xerostomia and Hyposalivation: Forecasted Estimates (till 2035)
18.1.5. Next Generation RNA Therapeutics Market for Inherited Bone Marrow Failure Syndromes: Forecasted Estimates (till 2035)
19.1. Next Generation RNA Therapeutics Market: Distribution by Route of Administration
19.1.1. Next Generation RNA Therapeutics Market for Intravenous Route: Forecasted Estimates (till 2035)
19.1.2. Next Generation RNA Therapeutics Market for Intramuscular Route: Forecasted Estimates (till 2035)
19.1.3. Next Generation RNA Therapeutics Market for Intratumoral Route: Forecasted Estimates (till 2035)
19.1.4. Next Generation RNA Therapeutics Market for Intraductal Route: Forecasted Estimates (till 2035)
20.1. Next Generation RNA Therapeutics Market: Distribution by Geographical Regions
20.1.1. Next Generation RNA Therapeutics Market in North America: Forecasted Estimates (till 2035)
20.1.1.1. Next Generation RNA Therapeutics Market in the US: Forecasted Estimates (till 2035)
20.1.2. Next Generation RNA Therapeutics Market in Europe: Forecasted Estimates (till 2035)
20.1.2.1. Next Generation RNA Therapeutics Market in the UK: Forecasted Estimates (till 2035)
20.1.2.2. Next Generation RNA Therapeutics Market in Germany: Forecasted Estimates (till 2035)
20.1.2.3. Next Generation RNA Therapeutics Market in France: Forecasted Estimates (till 2035)
20.1.2.4. Next Generation RNA Therapeutics Market in Italy: Forecasted Estimates (till 2035)
20.1.2.5. Next Generation RNA Therapeutics Market in Spain: Forecasted Estimates (till 2035)
20.1.2.6. Next Generation RNA Therapeutics Market in Rest of Europe: Forecasted Estimates (till 2035)
20.1.3. Next Generation RNA Therapeutics Market in Asia-Pacific: Forecasted Estimates (till 2035)
20.1.3.1. Next Generation RNA Therapeutics Market in Singapore: Forecasted Estimates (till 2035)
22.1. Next Generation RNA Therapeutics: Drug Sales Forecast
22.1.1. MTL-CEBPA
22.1.2. BNT 161 / PF-07926307
22.1.3. STX-001
22.1.4. RXRG001
22.1.5. EXG-34217
23.1. Next Generation RNA Therapeutics Market in North America: Distribution by Type of Modality
23.1.1. Next Generation RNA Therapeutics Market in North America for Therapeutics: Forecasted Estimates (till 2035)
23.1.2. Next Generation RNA Therapeutics Market in North America for Vaccines: Forecasted Estimates (till 2035)
23.2. Next Generation RNA Therapeutics Market in North America: Distribution by Type of Molecule
23.2.1. Next Generation RNA Therapeutics Market in North America for sacRNA: Forecasted Estimates (till 2035)
23.2.2. Next Generation RNA Therapeutics Market in North America for saRNA: Forecasted Estimates (till 2035)
23.2.3. Next Generation RNA Therapeutics Market in North America for circRNA: Forecasted Estimates (till 2035)
23.3. Next Generation RNA Therapeutics Market in North America: Distribution by Target Indication
23.3.1. Next Generation RNA Therapeutics Market in North America for Hepatocellular Carcinoma: Forecasted Estimates (till 2035)
23.3.2. Next Generation RNA Therapeutics Market in North America for Seasonal Influenza: Forecasted Estimates (till 2035)
23.3.3. Next Generation RNA Therapeutics Market in North America for Advanced Solid Tumors: Forecasted Estimates (till 2035)
23.3.4. Next Generation RNA Therapeutics Market in North America for Radiation-Induced Xerostomia and Hyposalivation: Forecasted Estimates (till 2035)
23.3.5. Next Generation RNA Therapeutics Market in North America for Inherited Bone Marrow Failure Syndromes: Forecasted Estimates (till 2035)
23.4. Next Generation RNA Therapeutics Market in North America: Distribution by Route of Administration
23.4.1. Next Generation RNA Therapeutics Market in North America for Intravenous Route: Forecasted Estimates (till 2035)
23.4.2. Next Generation RNA Therapeutics Market in North America for Intramuscular Route: Forecasted Estimates (till 2035)
23.4.3. Next Generation RNA Therapeutics Market in North America for Intratumoral Route: Forecasted Estimates (till 2035)
23.4.4. Next Generation RNA Therapeutics Market in North America for Intraductal Route: Forecasted Estimates (till 2035)
24.1. Next Generation RNA Therapeutics Market in Europe: Distribution by Type of Modality
24.1.1. Next Generation RNA Therapeutics Market in Europe for Therapeutics: Forecasted Estimates (till 2035)
24.1.2. Next Generation RNA Therapeutics Market in Europe for Vaccines: Forecasted Estimates (till 2035)
24.2. Next Generation RNA Therapeutics Market in Europe: Distribution by Type of Molecule
24.2.1. Next Generation RNA Therapeutics Market in Europe for sacRNA: Forecasted Estimates (till 2035)
24.2.2. Next Generation RNA Therapeutics Market in Europe for saRNA: Forecasted Estimates (till 2035)
24.2.3. Next Generation RNA Therapeutics Market in Europe for circRNA: Forecasted Estimates (till 2035)
24.3. Next Generation RNA Therapeutics Market in Europe: Distribution by Target Indication
24.3.1. Next Generation RNA Therapeutics Market in Europe for Hepatocellular Carcinoma: Forecasted Estimates (till 2035)
24.3.2. Next Generation RNA Therapeutics Market in Europe for Seasonal Influenza: Forecasted Estimates (till 2035)
24.3.3. Next Generation RNA Therapeutics Market in Europe for Advanced Solid Tumors: Forecasted Estimates (till 2035)
24.3.4. Next Generation RNA Therapeutics Market in Europe for Radiation-Induced Xerostomia and Hyposalivation: Forecasted Estimates (till 2035)
24.3.5. Next Generation RNA Therapeutics Market in Europe for Inherited Bone Marrow Failure Syndromes: Forecasted Estimates (till 2035)
24.4. Next Generation RNA Therapeutics Market in Europe: Distribution by Route of Administration
24.4.1. Next Generation RNA Therapeutics Market in Europe for Intravenous Route: Forecasted Estimates (till 2035)
24.4.2. Next Generation RNA Therapeutics Market in Europe for Intramuscular Route: Forecasted Estimates (till 2035)
24.4.3. Next Generation RNA Therapeutics Market in Europe for Intratumoral Route: Forecasted Estimates (till 2035)
24.4.4. Next Generation RNA Therapeutics Market in Europe for Intraductal Route: Forecasted Estimates (till 2035)
25.1. Next Generation RNA Therapeutics Market in Asia-Pacific: Distribution by Type of Modality
25.1.1. Next Generation RNA Therapeutics Market in Asia-Pacific for Therapeutics: Forecasted Estimates (till 2035)
25.1.2. Next Generation RNA Therapeutics Market in Asia-Pacific for Vaccines: Forecasted Estimates (till 2035)
25.2. Next Generation RNA Therapeutics Market in Asia-Pacific: Distribution by Type of Molecule
25.2.1. Next Generation RNA Therapeutics Market in Asia-Pacific for sacRNA: Forecasted Estimates (till 2035)
25.2.2. Next Generation RNA Therapeutics Market in Asia-Pacific for saRNA: Forecasted Estimates (till 2035)
25.2.3. Next Generation RNA Therapeutics Market in Asia-Pacific for circRNA: Forecasted Estimates (till 2035)
25.3. Next Generation RNA Therapeutics Market in Asia-Pacific: Distribution by Target Indication
25.3.1. Next Generation RNA Therapeutics Market in Asia-Pacific for Hepatocellular Carcinoma: Forecasted Estimates (till 2035)
25.3.2. Next Generation RNA Therapeutics Market in Asia-Pacific for Seasonal Influenza: Forecasted Estimates (till 2035)
25.3.3. Next Generation RNA Therapeutics Market in Asia-Pacific for Advanced Solid Tumors: Forecasted Estimates (till 2035)
25.3.4. Next Generation RNA Therapeutics Market in Asia-Pacific for Radiation-Induced Xerostomia and Hyposalivation: Forecasted Estimates (till 2035)
25.3.5. Next Generation RNA Therapeutics Market in Asia-Pacific for Inherited Bone Marrow Failure Syndromes: Forecasted Estimates (till 2035)
25.4. Next Generation RNA Therapeutics Market in Asia-Pacific: Distribution by Route of Administration
25.4.1. Next Generation RNA Therapeutics Market in Asia-Pacific for Intravenous Route: Forecasted Estimates (till 2035)
25.4.2. Next Generation RNA Therapeutics Market in Asia-Pacific for Intramuscular Route: Forecasted Estimates (till 2035)
25.4.3. Next Generation RNA Therapeutics Market in Asia-Pacific for Intratumoral Route: Forecasted Estimates (till 2035)
25.4.4. Next Generation RNA Therapeutics Market in Asia-Pacific for Intraductal Route: Forecasted Estimates (till 2035)
**Detailed information on Chapter 23 to 25 is available in the Excel Data Packs shared along with the report**
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Evolution of Next Generation RNA Therapeutics and Vaccines
Figure 6.2 Key Aspects of Next Generation RNA Molecules
Figure 6.3 Key Challenges Associated with Traditional RNA Modalities
Figure 6.4 Advantages of Using Next Generation RNA Modalities
Figure 7.1 Next Generation RNA Therapies: Distribution by Type of Modality
Figure 7.2 Next Generation RNA Therapies: Distribution by Type of Molecule
Figure 7.3 Next Generation RNA Therapies: Distribution by Delivery Vehicle
Figure 7.4 Next Generation RNA Therapies: Distribution by Stage of Development
Figure 7.5 Next Generation RNA Therapies: Distribution by Therapeutic Area
Figure 7.6 Most Active Players: Distribution by Number of Therapies
Figure 7.7 Clinical Stage Therapies: Distribution by Phase of Development
Figure 7.8 Clinical Stage Therapies: Distribution by Route of Administration
Figure 7.9 Clinical Stage Therapies: Distribution by Therapeutic Area
Figure 7.10 Therapy Developers Landscape: Distribution by Year of Establishment
Figure 7.11 Therapy Developers Landscape: Distribution by Company Size
Figure 7.12 Therapy Developers Landscape: Distribution by Location of Headquarters
Figure 7.13 saRNA Therapies: Distribution by Phase of Development
Figure 7.14 saRNA Therapies: Distribution by Therapeutic Area
Figure 7.15 Most Active Players: Distribution by Number of saRNA Therapies
Figure 7.16 circRNA Therapies: Distribution by Phase of Development
Figure 7.17 circRNA Therapies: Distribution by Therapeutic Area
Figure 7.18 Most Active Players: Distribution by Number of circRNA Therapies
Figure 8.1 Next Generation RNA Technologies: Distribution by Class of Molecule
Figure 8.2 Next Generation RNA Technologies: Distribution by Type of Molecule
Figure 8.3 Next Generation RNA Technologies: Distribution by Capabilities of the Technology
Figure 8.4 Next Generation RNA Technologies: Distribution by Therapeutic Area
Figure 8.5 Next Generation RNA Technologies: Distribution by Highest Stage of Development
Figure 8.6 Next Generation RNA Technologies: Distribution by Class of Molecule and Therapeutic Area
Figure 8.7 Next Generation RNA Technologies: Distribution by Class of Molecule and Highest Stage of Development
Figure 8.8 Next Generation RNA Technologies: Distribution by Type of Molecule and Capabilities of the Technology
Figure 8.9 Technology Developer Landscape: Distribution by Year of Establishment
Figure 8.10 Technology Developer Landscape: Distribution by Company Size
Figure 8.11 Technology Developer Landscape: Distribution by Location of Headquarters
Figure 8.12 Technology Developer Landscape: Distribution by Operational Model
Figure 9.1 BNT161: Estimated Sales
Figure 9.2 MTL-CEBPA: Estimated Sales
Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.5 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
Figure 10.6 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year
Figure 10.7 Clinical Trial Analysis: Distribution by Study Design
Figure 10.8 Clinical Trial Analysis: Distribution by Target Patient Population
Figure 10.9 Clinical Trial Analysis: Distribution by Patient Gender
Figure 10.10 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.12 Clinical Trial Analysis: Most Active Players by Number of Trials
Figure 10.13 Clinical Trial Analysis: Geographical Distribution of Trials and Number of Patients Enrolled
Figure 10.14 Clinical Trial Analysis: North America: Key Insights
Figure 10.15 Clinical Trial Analysis: Europe: Key Insights
Figure 10.16 Clinical Trial Analysis: Asia-Pacific: Key Insights
Figure 10.17 Clinical Trial Analysis: Rest of the World: Key Insights
Figure 11.1 Patent Analysis: Distribution by Publication Year
Figure 11.2 Patent Analysis: Distribution by Type of Patent
Figure 11.3 Patent Analysis: Distribution of Granted Patents and Patent Applications by Publication Year
Figure 11.4 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 11.5 Patent Analysis: Distribution by Application Year
Figure 11.6 Patent Analysis: Distribution by Patent Jurisdiction (Region)
Figure 11.7 Patent Analysis: Distribution by Patent Jurisdiction (Country)
Figure 11.8 Patent Analysis: Distribution by Patent Age
Figure 11.9 Leading Industry Players: Analysis by Number of Patents
Figure 11.10 Leading Non-Industry Players: Analysis by Number of Patents
Figure 11.11 Leading Individual Assignees: Analysis by Number of Patents
Figure 11.12 Patent Analysis: Distribution by CPC Symbols
Figure 11.13 Patent Benchmarking: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 11.14 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 11.15 Patent Valuation
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Molecule
Figure 12.5 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 12.6 Partnerships and Collaborations: Distribution by Focus Area of Partnership
Figure 12.7 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 12.8 Most Active Players: Distribution by Number of Partnerships
Figure 12.9 Partnerships and Collaborations: Local and International Deals
Figure 12.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 13.1 Funding and Investment Analysis: Cumulative Year-wise Trend
Figure 13.2 Funding and Investment Analysis: Distribution by Type of Funding
Figure 13.3 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 13.4 Funding and Investment Analysis: Distribution of Cumulative Amount Invested by Year (USD Million)
Figure 13.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 13.6 Funding and Investment Analysis: Distribution by Geography
Figure 13.7 Funding and Investment Analysis: Distribution by Type of Molecule
Figure 13.8 Funding and Investment Analysis: Distribution by Purpose of Funding
Figure 13.9 Funding and Investment Analysis: Distribution by Stage of Development
Figure 13.10 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 13.11 Most Active Players: Analysis by Number of Funding Instances
Figure 13.12 Most Active Players: Analysis by Amount Invested (USD Million)
Figure 13.13 Most Active Investors: Analysis by Number of Funding Instances
Figure 14.1 Most Active Players by Number of Big Pharma Initiatives
Figure 14.2 Big Player Initiatives: Distribution by Year of Initiative
Figure 14.3 Big Player Initiatives: Distribution by Type of Initiative
Figure 14.4 Big Player Initiatives: Distribution by Focus Area of Initiative
Figure 14.5 Big Player Initiatives: Distribution by Purpose of Initiative
Figure 14.6 Big Player Initiatives: Distribution by Type of Molecule
Figure 14.7 Big Player Initiatives: Distribution by Therapeutic Area
Figure 14.8 Big Player Initiatives: Distribution by Therapeutic Area
Figure 14.9 Big Player Initiatives: Distribution by Location of Headquarters
Figure 15.1 Global Next Generation RNA Therapeutics Market, Forecasted Estimates (till 2035): Base Scenario
Figure 15.2 Global Next Generation RNA Therapeutics Market, Forecasted Estimates (till 2035): Conservative Scenario
Figure 15.3 Global Next Generation RNA Therapeutics Market, Forecasted Estimates (till 2035): Optimistic Scenario
Figure 16.1 Next Generation RNA Therapeutics Market: Distribution by Type of Modality
Figure 16.2 Next Generation RNA Therapeutics Market for Therapeutics, Forecasted Estimates (till 2035)
Figure 16.3 Next Generation RNA Therapeutics Market for Vaccines, Forecasted Estimates (till 2035)
Figure 17.1 Next Generation RNA Therapeutics Market: Distribution by Type of Molecule
Figure 17.2 Next Generation RNA Therapeutics Market for sacRNA, Forecasted Estimates (till 2035)
Figure 17.3 Next Generation RNA Therapeutics Market for saRNA, Forecasted Estimates (till 2035)
Figure 17.4 Next Generation RNA Therapeutics Market for circRNA, Forecasted Estimates (till 2035)
Figure 18.1 Next Generation RNA Therapeutics Market: Distribution by Target Indication
Figure 18.2 Next Generation RNA Therapeutics Market for Hepatocellular Carcinoma, Forecasted Estimates (till 2035)
Figure 18.3 Next Generation RNA Therapeutics Market for Seasonal Influenza, Forecasted Estimates (till 2035)
Figure 18.4 Next Generation RNA Therapeutics Market for Advanced Solid Tumors, Forecasted Estimates (till 2035)
Figure 18.5 Next Generation RNA Therapeutics Market for Radiation-Induced Xerostomia and Hyposalivation, Forecasted Estimates (till 2035)
Figure 18.6 Next Generation RNA Therapeutics Market for Inherited Bone Marrow Failure Syndromes, Forecasted Estimates (till 2035)
Figure 19.1 Next Generation RNA Therapeutics Market: Distribution by Route of Administration
Figure 19.2 Next Generation RNA Therapeutics Market for Intravenous Route, Forecasted Estimates (till 2035)
Figure 19.3 Next Generation RNA Therapeutics Market for Intramuscular Route, Forecasted Estimates (till 2035)
Figure 19.4 Next Generation RNA Therapeutics Market for Intratumoral Route, Forecasted Estimates (till 2035)
Figure 19.5 Next Generation RNA Therapeutics Market for Intraductal Route, Forecasted Estimates (till 2035)
Figure 20.1 Next Generation RNA Therapeutics Market: Distribution by Geographical Region
Figure 20.2 Next Generation RNA Therapeutics Market in North America, Forecasted Estimates (till 2035)
Figure 20.3 Next Generation RNA Therapeutics Market in the US, Forecasted Estimates (till 2035)
Figure 20.4 Next Generation RNA Therapeutics Market in Europe, Forecasted Estimates (till 2035)
Figure 20.5 Next Generation RNA Therapeutics Market in the UK, Forecasted Estimates (till 2035)
Figure 20.6 Next Generation RNA Therapeutics Market in Germany, Forecasted Estimates (till 2035)
Figure 20.7 Next Generation RNA Therapeutics Market in France, Forecasted Estimates (till 2035)
Figure 20.8 Next Generation RNA Therapeutics Market in Italy, Forecasted Estimates (till 2035)
Figure 20.9 Next Generation RNA Therapeutics Market in Spain, Forecasted Estimates (till 2035)
Figure 20.10 Next Generation RNA Therapeutics Market in Rest of Europe, Forecasted Estimates (till 2035)
Figure 20.11 Next Generation RNA Therapeutics Market in Asia-Pacific, Forecasted Estimates (till 2035)
Figure 20.12 Next Generation RNA Therapeutics Market in Singapore, Forecasted Estimates (till 2035)
Figure 21.1 Next Generation RNA Therapeutics Market: Distribution by Distribution by Leading Players, 2032 (based on revenues generated)
Figure 21.2 Next Generation RNA Therapeutics Market: Distribution by Distribution by Leading Players, 2035 (based on revenues generated)
Figure 22.1 Next Generation RNA Therapeutics Market: Sales Forecast for MTL-CEBPA, Forecasted Estimates (till 2035) (USD Million)
Figure 22.2 Next Generation RNA Therapeutics Market: Sales Forecast for BNT 161, Forecasted Estimates (till 2035) (USD Million)
Figure 22.3 Next Generation RNA Therapeutics Market: Sales Forecast for STX-001, Forecasted Estimates (till 2035) (USD Million)
Figure 22.4 Next Generation RNA Therapeutics Market: Sales Forecast for RXRG001, Forecasted Estimates (till 2035) (USD Million)
Figure 22.5 Next Generation RNA Therapeutics Market: Sales Forecast for EXG-34217, Forecasted Estimates (till 2035) (USD Million)
Table 7.1 List of Next Generation RNA Therapeutics and RNA Vaccines
Table 7.2 List of Clinical Stage Next Generation RNA Therapeutics and RNA Vaccines
Table 7.3 List of Next Generation RNA Therapeutic and RNA Vaccine Developers
Table 8.1 List of Next Generation RNA Technologies
Table 8.2 List of Next Generation RNA Technology / Platform Developers
Table 10.1 RNA Therapeutics and RNA Vaccines: List of Clinical Trials
Table 11.1 RNA Therapeutics and RNA Vaccines: List of Published Patents
Table 12.1 RNA Therapeutics and RNA Vaccines: List of Partnerships and Collaborations
Table 13.1 RNA Therapeutics and RNA Vaccines: List of Funding and Investments
Table 14.1 RNA Therapeutics and RNA Vaccines: List of Big Pharma Initiatives
Table 15.1 RNA Therapeutics and RNA Vaccines: List of Forecasted Drugs
Table 27.1 Next Generation RNA Therapies: Distribution by Type of Modality
Table 27.2 Next Generation RNA Therapies: Distribution by Type of Molecule
Table 27.3 Next Generation RNA Therapies: Distribution by Delivery Vehicle
Table 27.4 Next Generation RNA Therapies: Distribution by Stage of Development
Table 27.5 Next Generation RNA Therapies: Distribution by Therapeutic Area
Table 27.6 Most Active Players: Distribution by Number of Therapies
Table 27.7 Clinical Stage Therapies: Distribution by Phase of Development
Table 27.8 Clinical Stage Therapies: Distribution by Route of Administration
Table 27.9 Clinical Stage Therapies: Distribution by Therapeutic Area
Table 27.10 Therapy Developers Landscape: Distribution by Year of Establishment
Table 27.11 Therapy Developers Landscape: Distribution by Company Size
Table 27.12 Therapy Developers Landscape: Distribution by Location of Headquarters
Table 27.13 saRNA Therapies: Distribution by Phase of Development
Table 27.14 saRNA Therapies: Distribution by Therapeutic Area
Table 27.15 Most Active Players: Distribution by Number of saRNA Therapies
Table 27.16 circRNA Therapies: Distribution by Phase of Development
Table 27.17 circRNA Therapies: Distribution by Therapeutic Area
Table 27.18 Most Active Players: Distribution by Number of circRNA Therapies
Table 27.19 Next Generation RNA Technologies: Distribution by Class of Molecule
Table 27.20 Next Generation RNA Technologies: Distribution by Type of Molecule
Table 27.21 Next Generation RNA Technologies: Distribution by Capabilities of the Technology
Table 27.22 Next Generation RNA Technologies: Distribution by Therapeutic Area
Table 27.23 Next Generation RNA Technologies: Distribution by Highest Stage of Development
Table 27.24 Next Generation RNA Technologies: Distribution by Class of Molecule and Therapeutic Area
Table 27.25 Next Generation RNA Technologies: Distribution by Class of Molecule and Highest Stage of Development
Table 27.26 Next Generation RNA Technologies: Distribution by Type of Molecule and Capabilities of the Technology
Table 27.27 Technology Developer Landscape: Distribution by Year of Establishment
Table 27.28 Technology Developer Landscape: Distribution by Company Size
Table 27.29 Technology Developer Landscape: Distribution by Location of Headquarters
Table 27.30 Technology Developer Landscape: Distribution by Operational Model
Table 27.31 BNT161: Estimated Sales
Table 27.32 MTL-CEBPA: Estimated Sales
Table 27.33 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 27.34 Clinical Trial Analysis: Distribution by Trial Status
Table 27.35 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 27.36 Clinical Trial Analysis: Distribution by Trial Phase
Table 27.37 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
Table 27.38 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year
Table 27.39 Clinical Trial Analysis: Distribution by Study Design
Table 27.40 Clinical Trial Analysis: Distribution by Target Patient Population
Table 27.41 Clinical Trial Analysis: Distribution by Patient Gender
Table 27.42 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 27.43 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 27.44 Clinical Trial Analysis: Most Active Players by Number of Trials
Table 27.45 Clinical Trial Analysis: Geographical Distribution of Trials and Number of Patients Enrolled
Table 27.46 Patent Analysis: Distribution by Publication Year
Table 27.47 Patent Analysis: Distribution by Type of Patent
Table 27.48 Patent Analysis: Distribution of Granted Patents and Patent Applications by Publication Year
Table 27.49 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 27.50 Patent Analysis: Distribution by Application Year
Table 27.51 Patent Analysis: Distribution by Patent Jurisdiction (Region)
Table 27.52 Patent Analysis: Distribution by Patent Jurisdiction (Country)
Table 27.53 Patent Analysis: Distribution by Patent Age
Table 27.54 Leading Industry Players: Analysis by Number of Patents
Table 27.55 Leading Non-Industry Players: Analysis by Number of Patents
Table 27.56 Leading Individual Assignees: Analysis by Number of Patents
Table 27.57 Patent Valuation
Table 27.58 Partnerships and Collaborations: Cumulative Year-wise Trend
Table 27.59 Partnerships and Collaborations: Distribution by Type of Partnership
Table 27.60 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 27.61 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Molecule
Table 27.62 Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 27.63 Partnerships and Collaborations: Distribution by Focus Area of Partnership
Table 27.64 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 27.65 Most Active Players: Distribution by Number of Partnerships
Table 27.66 Partnerships and Collaborations: Local and International Deals
Table 27.67 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 27.68 Funding and Investment Analysis: Cumulative Year-wise Trend
Table 27.69 Funding and Investment Analysis: Distribution by Type of Funding
Table 27.70 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 27.71 Funding and Investment Analysis: Distribution of Cumulative Amount Invested by Year (USD Million)
Table 27.72 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 27.73 Funding and Investment Analysis: Distribution by Geography
Table 27.74 Funding and Investment Analysis: Distribution by Type of Molecule
Table 27.75 Funding and Investment Analysis: Distribution by Purpose of Funding
Table 27.76 Funding and Investment Analysis: Distribution by Stage of Development
Table 27.77 Funding and Investment Analysis: Distribution by Therapeutic Area
Table 27.78 Most Active Players: Analysis by Number of Funding Instances
Table 27.79 Most Active Players: Analysis by Amount Invested (USD Million)
Table 27.80 Most Active Investors: Analysis by Number of Funding Instances
Table 27.81 Most Active Players by Number of Big Pharma Initiatives
Table 27.82 Big Player Initiatives: Distribution by Year of Initiative
Table 27.83 Big Player Initiatives: Distribution by Type of Initiative
Table 27.84 Big Player Initiatives: Distribution by Focus Area of Initiative
Table 27.85 Big Player Initiatives: Distribution by Purpose of Initiative
Table 27.86 Big Player Initiatives: Distribution by Type of Molecule
Table 27.87 Big Player Initiatives: Distribution by Therapeutic Area
Table 27.88 Big Player Initiatives: Distribution by Therapeutic Area
Table 27.89 Big Player Initiatives: Distribution by Location of Headquarters
Table 27.90 Global Next Generation RNA Therapeutics Market, Forecasted Estimates (till 2035): Base Scenario (USD Million)
Table 27.91 Global Next Generation RNA Therapeutics Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Table 27.92 Global Next Generation RNA Therapeutics Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Table 27.93 Next Generation RNA Therapeutics Market: Distribution by Type of Modality
Table 27.94 Next Generation RNA Therapeutics Market for Therapeutics, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.95 Next Generation RNA Therapeutics Market for Vaccines, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.96 Next Generation RNA Therapeutics Market: Distribution by Type of Molecule
Table 27.97 Next Generation RNA Therapeutics Market for sacRNA, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.98 Next Generation RNA Therapeutics Market for saRNA, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.99 Next Generation RNA Therapeutics Market for circRNA, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.100 Next Generation RNA Therapeutics Market: Distribution by Target Indication
Table 27.101 Next Generation RNA Therapeutics Market for Hepatocellular Carcinoma, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.102 Next Generation RNA Therapeutics Market for Seasonal Influenza, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.103 Next Generation RNA Therapeutics Market for Advanced Solid Tumors, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.104 Next Generation RNA Therapeutics Market for Radiation-Induced Xerostomia and Hyposalivation, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.105 Next Generation RNA Therapeutics Market for Inherited Bone Marrow Failure Syndromes, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.106 Next Generation RNA Therapeutics Market: Distribution by Route of Administration
Table 27.107 Next Generation RNA Therapeutics Market for Intravenous Route, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.108 Next Generation RNA Therapeutics Market for Intramuscular Route, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.109 Next Generation RNA Therapeutics Market for Intratumoral Route, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.110 Next Generation RNA Therapeutics Market for Intraductal Route, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.111 Next Generation RNA Therapeutics Market: Distribution by Geographical Region
Table 27.112 Next Generation RNA Therapeutics Market in North America, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.113 Next Generation RNA Therapeutics Market in the US, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.114 Next Generation RNA Therapeutics Market in Europe, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.115 Next Generation RNA Therapeutics Market in the UK, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.116 Next Generation RNA Therapeutics Market in Germany, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.117 Next Generation RNA Therapeutics Market in France, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.118 Next Generation RNA Therapeutics Market in Italy, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.119 Next Generation RNA Therapeutics Market in Spain, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.120 Next Generation RNA Therapeutics Market in Rest of Europe, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.121 Next Generation RNA Therapeutics Market in Asia-Pacific, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.122 Next Generation RNA Therapeutics Market in Singapore, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)
Table 27.123 Next Generation RNA Therapeutics Market: Distribution by Distribution by Leading Players, 2032 (based on revenues generated)
Table 27.124 Next Generation RNA Therapeutics Market: Distribution by Distribution by Leading Players, 2035 (based on revenues generated)
Table 27.125 Next Generation RNA Therapeutics Market: Sales Forecast for MTL-CEBPA, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million) (USD Million)
Table 27.126 Next Generation RNA Therapeutics Market: Sales Forecast for BNT 161, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million) (USD Million)
Table 27.127 Next Generation RNA Therapeutics Market: Sales Forecast for STX-001, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million) (USD Million)
Table 27.128 Next Generation RNA Therapeutics Market: Sales Forecast for RXRG001, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million) (USD Million)
Table 27.129 Next Generation RNA Therapeutics Market: Sales Forecast for EXG-34217, Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million) (USD Million)
Please reach out to our team for more details.